| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Barrett Esophagus | 67 | 2026 | 358 | 18.050 |
Why?
|
| Esophageal Neoplasms | 63 | 2026 | 392 | 16.930 |
Why?
|
| Adenocarcinoma | 59 | 2025 | 999 | 13.030 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 23 | 2026 | 404 | 7.580 |
Why?
|
| Stomach Neoplasms | 18 | 2024 | 579 | 7.100 |
Why?
|
| Carcinoma, Hepatocellular | 31 | 2025 | 999 | 6.660 |
Why?
|
| Liver Neoplasms | 34 | 2025 | 1393 | 6.640 |
Why?
|
| Helicobacter Infections | 18 | 2025 | 1301 | 4.760 |
Why?
|
| Precancerous Conditions | 14 | 2025 | 283 | 4.680 |
Why?
|
| Alcohol Drinking | 11 | 2024 | 347 | 4.370 |
Why?
|
| Liver Cirrhosis | 22 | 2025 | 901 | 4.300 |
Why?
|
| Gastroesophageal Reflux | 20 | 2024 | 333 | 3.890 |
Why?
|
| Helicobacter pylori | 17 | 2025 | 1358 | 3.870 |
Why?
|
| Risk Factors | 92 | 2026 | 10965 | 3.760 |
Why?
|
| Middle Aged | 122 | 2026 | 28897 | 2.930 |
Why?
|
| Incidence | 46 | 2025 | 3349 | 2.840 |
Why?
|
| Aged | 96 | 2026 | 21263 | 2.640 |
Why?
|
| Obesity | 22 | 2024 | 2390 | 2.610 |
Why?
|
| Early Detection of Cancer | 10 | 2025 | 418 | 2.450 |
Why?
|
| Humans | 214 | 2026 | 131781 | 2.420 |
Why?
|
| Male | 139 | 2026 | 65290 | 2.230 |
Why?
|
| Colorectal Neoplasms | 11 | 2024 | 639 | 2.230 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2024 | 256 | 2.110 |
Why?
|
| United States | 49 | 2026 | 11815 | 2.090 |
Why?
|
| Female | 137 | 2026 | 71221 | 2.050 |
Why?
|
| Smoking | 11 | 2023 | 927 | 1.970 |
Why?
|
| Life Style | 7 | 2022 | 444 | 1.950 |
Why?
|
| Adult | 77 | 2026 | 31710 | 1.850 |
Why?
|
| Neoplasms | 9 | 2024 | 2963 | 1.810 |
Why?
|
| Veterans | 17 | 2025 | 1797 | 1.790 |
Why?
|
| Risk Assessment | 32 | 2025 | 3696 | 1.760 |
Why?
|
| Case-Control Studies | 34 | 2026 | 3451 | 1.750 |
Why?
|
| Proton Pump Inhibitors | 9 | 2023 | 278 | 1.660 |
Why?
|
| Mendelian Randomization Analysis | 9 | 2021 | 97 | 1.590 |
Why?
|
| Cross-Sectional Studies | 25 | 2025 | 3838 | 1.580 |
Why?
|
| Prevalence | 23 | 2025 | 2695 | 1.520 |
Why?
|
| Esophagoscopy | 8 | 2025 | 175 | 1.510 |
Why?
|
| Health Status Disparities | 6 | 2024 | 277 | 1.500 |
Why?
|
| Metaplasia | 11 | 2022 | 216 | 1.420 |
Why?
|
| Demography | 6 | 2021 | 243 | 1.380 |
Why?
|
| Population Surveillance | 5 | 2022 | 397 | 1.360 |
Why?
|
| Histamine H2 Antagonists | 3 | 2019 | 49 | 1.300 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2026 | 2859 | 1.280 |
Why?
|
| Odds Ratio | 15 | 2021 | 1235 | 1.280 |
Why?
|
| Aged, 80 and over | 26 | 2024 | 6916 | 1.270 |
Why?
|
| Registries | 17 | 2024 | 1598 | 1.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 743 | 1.260 |
Why?
|
| Texas | 19 | 2025 | 3622 | 1.240 |
Why?
|
| Logistic Models | 17 | 2026 | 1838 | 1.170 |
Why?
|
| Stomach | 2 | 2022 | 274 | 1.140 |
Why?
|
| Veterans Health | 2 | 2020 | 171 | 1.140 |
Why?
|
| Disease Progression | 15 | 2026 | 2221 | 1.140 |
Why?
|
| Socioeconomic Factors | 9 | 2024 | 898 | 1.130 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2022 | 759 | 1.120 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 502 | 1.080 |
Why?
|
| Rectal Neoplasms | 2 | 2021 | 78 | 1.070 |
Why?
|
| Exercise | 5 | 2025 | 866 | 1.060 |
Why?
|
| Body Mass Index | 9 | 2024 | 1695 | 1.050 |
Why?
|
| Models, Statistical | 3 | 2016 | 493 | 1.040 |
Why?
|
| Phospholipases A2, Calcium-Independent | 2 | 2024 | 19 | 1.030 |
Why?
|
| Colonic Polyps | 3 | 2023 | 86 | 1.030 |
Why?
|
| Intestines | 3 | 2021 | 592 | 1.030 |
Why?
|
| Decision Support Techniques | 5 | 2020 | 298 | 1.000 |
Why?
|
| Nutrition Surveys | 7 | 2022 | 327 | 0.990 |
Why?
|
| Mexican Americans | 2 | 2018 | 166 | 0.980 |
Why?
|
| Body Height | 4 | 2018 | 196 | 0.970 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2018 | 302 | 0.960 |
Why?
|
| Pancreatic Neoplasms | 2 | 2024 | 732 | 0.960 |
Why?
|
| Cohort Studies | 22 | 2025 | 5122 | 0.950 |
Why?
|
| Colonic Neoplasms | 2 | 2021 | 265 | 0.940 |
Why?
|
| Global Health | 5 | 2022 | 632 | 0.920 |
Why?
|
| Endoscopy, Digestive System | 7 | 2025 | 154 | 0.920 |
Why?
|
| Elasticity Imaging Techniques | 3 | 2024 | 152 | 0.910 |
Why?
|
| Anthropometry | 2 | 2017 | 190 | 0.890 |
Why?
|
| Predictive Value of Tests | 14 | 2025 | 2299 | 0.880 |
Why?
|
| Rural Population | 3 | 2024 | 260 | 0.870 |
Why?
|
| Aspirin | 3 | 2016 | 216 | 0.870 |
Why?
|
| Primary Health Care | 5 | 2025 | 791 | 0.860 |
Why?
|
| Hepatitis C | 3 | 2023 | 390 | 0.860 |
Why?
|
| Antibodies, Bacterial | 2 | 2025 | 427 | 0.860 |
Why?
|
| Esophagogastric Junction | 2 | 2016 | 36 | 0.850 |
Why?
|
| Specimen Handling | 1 | 2024 | 149 | 0.820 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2026 | 3416 | 0.820 |
Why?
|
| Hepatitis C, Chronic | 2 | 2018 | 367 | 0.790 |
Why?
|
| Leptin | 2 | 2015 | 219 | 0.790 |
Why?
|
| Young Adult | 24 | 2024 | 10102 | 0.780 |
Why?
|
| Self Care | 1 | 2024 | 231 | 0.770 |
Why?
|
| SEER Program | 6 | 2024 | 210 | 0.760 |
Why?
|
| Endoscopy, Gastrointestinal | 7 | 2023 | 233 | 0.760 |
Why?
|
| Gallbladder Neoplasms | 1 | 2022 | 15 | 0.740 |
Why?
|
| Sleep | 1 | 2025 | 373 | 0.740 |
Why?
|
| Prognosis | 13 | 2024 | 4953 | 0.740 |
Why?
|
| Minority Groups | 2 | 2020 | 256 | 0.700 |
Why?
|
| Tobacco Smoking | 1 | 2021 | 20 | 0.700 |
Why?
|
| Urban Population | 1 | 2023 | 281 | 0.700 |
Why?
|
| Retrospective Studies | 29 | 2025 | 17667 | 0.700 |
Why?
|
| Liver Transplantation | 4 | 2025 | 1133 | 0.690 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 30 | 0.640 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 389 | 0.630 |
Why?
|
| Prospective Studies | 18 | 2025 | 6509 | 0.630 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 505 | 0.630 |
Why?
|
| United States Department of Veterans Affairs | 5 | 2021 | 713 | 0.620 |
Why?
|
| Electric Impedance | 2 | 2017 | 72 | 0.620 |
Why?
|
| Stomach Diseases | 1 | 2020 | 56 | 0.610 |
Why?
|
| Obesity, Abdominal | 2 | 2016 | 41 | 0.590 |
Why?
|
| Electronic Health Records | 4 | 2024 | 810 | 0.590 |
Why?
|
| Diet | 5 | 2023 | 1119 | 0.580 |
Why?
|
| Genome-Wide Association Study | 14 | 2026 | 1844 | 0.540 |
Why?
|
| Virus Diseases | 1 | 2020 | 285 | 0.540 |
Why?
|
| Endoscopic Mucosal Resection | 3 | 2024 | 81 | 0.540 |
Why?
|
| Klatskin Tumor | 1 | 2017 | 10 | 0.530 |
Why?
|
| Follow-Up Studies | 8 | 2024 | 5297 | 0.530 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 104 | 0.510 |
Why?
|
| Multivariate Analysis | 7 | 2021 | 1406 | 0.500 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1217 | 0.490 |
Why?
|
| Acculturation | 1 | 2016 | 61 | 0.480 |
Why?
|
| Overweight | 3 | 2023 | 377 | 0.480 |
Why?
|
| Metabolic Syndrome | 2 | 2021 | 363 | 0.480 |
Why?
|
| Fibrosis | 3 | 2022 | 416 | 0.480 |
Why?
|
| Tea | 1 | 2015 | 18 | 0.480 |
Why?
|
| Biopsy | 5 | 2025 | 1252 | 0.480 |
Why?
|
| Survival Analysis | 7 | 2019 | 1522 | 0.470 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 84 | 0.470 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 126 | 0.470 |
Why?
|
| Coffee | 1 | 2015 | 30 | 0.470 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 131 | 0.470 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 229 | 0.470 |
Why?
|
| Cold Temperature | 1 | 2015 | 81 | 0.470 |
Why?
|
| Serum | 1 | 2015 | 45 | 0.460 |
Why?
|
| Hot Temperature | 1 | 2015 | 144 | 0.450 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 904 | 0.450 |
Why?
|
| Europe | 6 | 2024 | 373 | 0.450 |
Why?
|
| Adiponectin | 1 | 2015 | 124 | 0.440 |
Why?
|
| Chemoprevention | 1 | 2015 | 51 | 0.440 |
Why?
|
| Environmental Exposure | 1 | 2018 | 291 | 0.440 |
Why?
|
| Adipokines | 1 | 2015 | 121 | 0.440 |
Why?
|
| Models, Genetic | 1 | 2017 | 752 | 0.440 |
Why?
|
| Cost of Illness | 1 | 2016 | 291 | 0.430 |
Why?
|
| Adipose Tissue | 1 | 2017 | 495 | 0.420 |
Why?
|
| Melatonin | 1 | 2014 | 30 | 0.420 |
Why?
|
| Pregnancy Outcome | 2 | 2014 | 630 | 0.410 |
Why?
|
| Australia | 7 | 2017 | 176 | 0.410 |
Why?
|
| Birth Weight | 1 | 2015 | 346 | 0.410 |
Why?
|
| Survival Rate | 4 | 2024 | 2151 | 0.410 |
Why?
|
| Alanine Transaminase | 3 | 2020 | 156 | 0.400 |
Why?
|
| Acyltransferases | 2 | 2024 | 62 | 0.400 |
Why?
|
| Age Factors | 7 | 2020 | 2872 | 0.400 |
Why?
|
| Proportional Hazards Models | 6 | 2024 | 1405 | 0.400 |
Why?
|
| Melanoma | 1 | 2020 | 921 | 0.390 |
Why?
|
| Risk | 7 | 2020 | 739 | 0.390 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 340 | 0.380 |
Why?
|
| Algorithms | 3 | 2022 | 1685 | 0.380 |
Why?
|
| ROC Curve | 5 | 2021 | 623 | 0.380 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2023 | 61 | 0.380 |
Why?
|
| Adiposity | 1 | 2014 | 207 | 0.370 |
Why?
|
| Liver Diseases | 1 | 2016 | 383 | 0.370 |
Why?
|
| Age Distribution | 4 | 2022 | 429 | 0.370 |
Why?
|
| Safety-net Providers | 2 | 2025 | 88 | 0.360 |
Why?
|
| Mortality | 2 | 2024 | 261 | 0.360 |
Why?
|
| Sex Factors | 8 | 2020 | 1347 | 0.360 |
Why?
|
| Inflammation | 2 | 2018 | 1493 | 0.360 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1617 | 0.350 |
Why?
|
| Premature Birth | 1 | 2015 | 414 | 0.340 |
Why?
|
| Gastroenterology | 3 | 2025 | 220 | 0.340 |
Why?
|
| HIV Infections | 3 | 2019 | 2037 | 0.330 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2011 | 76 | 0.330 |
Why?
|
| Acetaminophen | 1 | 2011 | 97 | 0.330 |
Why?
|
| Insulin | 1 | 2015 | 1151 | 0.320 |
Why?
|
| Time Factors | 7 | 2020 | 6279 | 0.320 |
Why?
|
| Guideline Adherence | 2 | 2024 | 393 | 0.320 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 1322 | 0.320 |
Why?
|
| Colonoscopy | 3 | 2023 | 247 | 0.310 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 216 | 0.300 |
Why?
|
| United Kingdom | 6 | 2019 | 255 | 0.300 |
Why?
|
| Biomarkers | 2 | 2020 | 3411 | 0.290 |
Why?
|
| Area Under Curve | 4 | 2021 | 320 | 0.290 |
Why?
|
| Cytokines | 2 | 2016 | 1348 | 0.290 |
Why?
|
| Vitamin D | 2 | 2021 | 194 | 0.270 |
Why?
|
| Adolescent | 14 | 2021 | 20994 | 0.270 |
Why?
|
| Sarcopenia | 2 | 2025 | 56 | 0.270 |
Why?
|
| Liver | 3 | 2026 | 1799 | 0.270 |
Why?
|
| Meta-Analysis as Topic | 3 | 2024 | 169 | 0.270 |
Why?
|
| Databases, Factual | 4 | 2021 | 1224 | 0.260 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2018 | 131 | 0.260 |
Why?
|
| Lipase | 2 | 2024 | 88 | 0.250 |
Why?
|
| Linkage Disequilibrium | 2 | 2025 | 318 | 0.250 |
Why?
|
| Aspartate Aminotransferases | 2 | 2016 | 79 | 0.250 |
Why?
|
| Genetic Loci | 2 | 2026 | 359 | 0.250 |
Why?
|
| Severity of Illness Index | 3 | 2023 | 3094 | 0.250 |
Why?
|
| Confidence Intervals | 2 | 2019 | 272 | 0.240 |
Why?
|
| Hyperplasia | 2 | 2022 | 189 | 0.230 |
Why?
|
| Seroepidemiologic Studies | 1 | 2025 | 167 | 0.230 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 373 | 0.220 |
Why?
|
| Gastritis | 2 | 2019 | 372 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1280 | 0.220 |
Why?
|
| Recurrence | 4 | 2018 | 1483 | 0.220 |
Why?
|
| Ablation Techniques | 2 | 2024 | 31 | 0.220 |
Why?
|
| Critical Pathways | 1 | 2025 | 74 | 0.220 |
Why?
|
| Genotype | 3 | 2022 | 2655 | 0.210 |
Why?
|
| Hospitals, Urban | 1 | 2024 | 99 | 0.210 |
Why?
|
| Residence Characteristics | 2 | 2024 | 293 | 0.210 |
Why?
|
| Diet, Mediterranean | 1 | 2023 | 19 | 0.200 |
Why?
|
| Gastrectomy | 1 | 2024 | 107 | 0.200 |
Why?
|
| Ovarian Neoplasms | 2 | 2018 | 455 | 0.190 |
Why?
|
| Arsenic | 1 | 2023 | 48 | 0.190 |
Why?
|
| Postoperative Complications | 2 | 2025 | 3134 | 0.190 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 810 | 0.190 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 259 | 0.180 |
Why?
|
| Frailty | 1 | 2024 | 141 | 0.180 |
Why?
|
| Hospitals, Veterans | 3 | 2018 | 346 | 0.180 |
Why?
|
| Sensitivity and Specificity | 4 | 2025 | 2148 | 0.180 |
Why?
|
| Natural Language Processing | 1 | 2022 | 72 | 0.180 |
Why?
|
| Esophagitis, Peptic | 1 | 2021 | 34 | 0.170 |
Why?
|
| Gastric Mucosa | 2 | 2022 | 491 | 0.170 |
Why?
|
| Social Class | 1 | 2023 | 212 | 0.170 |
Why?
|
| Machine Learning | 1 | 2025 | 375 | 0.170 |
Why?
|
| Waist-Hip Ratio | 3 | 2019 | 54 | 0.170 |
Why?
|
| Physical Fitness | 1 | 2021 | 89 | 0.170 |
Why?
|
| Cerebral Hemorrhage | 1 | 2002 | 156 | 0.170 |
Why?
|
| Principal Component Analysis | 2 | 2018 | 153 | 0.170 |
Why?
|
| Hysterectomy | 1 | 2023 | 205 | 0.170 |
Why?
|
| Medicare | 2 | 2022 | 439 | 0.170 |
Why?
|
| North America | 2 | 2019 | 257 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 2993 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 1413 | 0.160 |
Why?
|
| Hepacivirus | 1 | 2022 | 273 | 0.160 |
Why?
|
| Diet Records | 1 | 2020 | 70 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2024 | 1457 | 0.160 |
Why?
|
| Nutritive Value | 1 | 2020 | 83 | 0.160 |
Why?
|
| Dietary Fiber | 1 | 2020 | 78 | 0.160 |
Why?
|
| Gene-Environment Interaction | 2 | 2017 | 128 | 0.160 |
Why?
|
| Hepatitis B | 1 | 2021 | 174 | 0.160 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2020 | 90 | 0.160 |
Why?
|
| Dietary Carbohydrates | 1 | 2020 | 108 | 0.150 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 1069 | 0.150 |
Why?
|
| Cholesterol | 1 | 2002 | 541 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1304 | 0.150 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1610 | 0.150 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 4053 | 0.150 |
Why?
|
| Gene Expression Profiling | 1 | 2026 | 1835 | 0.150 |
Why?
|
| Genetic Pleiotropy | 1 | 2018 | 26 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 228 | 0.150 |
Why?
|
| Fruit | 1 | 2020 | 234 | 0.140 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 133 | 0.140 |
Why?
|
| Self Report | 2 | 2018 | 562 | 0.140 |
Why?
|
| Gastric Acid | 1 | 2018 | 55 | 0.140 |
Why?
|
| Capsule Endoscopy | 1 | 2018 | 20 | 0.140 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 307 | 0.140 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 69 | 0.140 |
Why?
|
| Omeprazole | 1 | 2018 | 101 | 0.140 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 130 | 0.140 |
Why?
|
| Gene Expression Regulation | 1 | 2026 | 2353 | 0.130 |
Why?
|
| Feeding Behavior | 1 | 2023 | 724 | 0.130 |
Why?
|
| Sex Distribution | 2 | 2016 | 321 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2019 | 773 | 0.130 |
Why?
|
| Energy Intake | 1 | 2020 | 501 | 0.130 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 146 | 0.130 |
Why?
|
| Software | 1 | 2022 | 752 | 0.130 |
Why?
|
| Work Schedule Tolerance | 1 | 2016 | 41 | 0.130 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 20 | 0.130 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2017 | 89 | 0.120 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 173 | 0.120 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2016 | 28 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 803 | 0.120 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 51 | 0.120 |
Why?
|
| Cause of Death | 1 | 2019 | 510 | 0.120 |
Why?
|
| Protective Factors | 1 | 2016 | 93 | 0.120 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 225 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 237 | 0.120 |
Why?
|
| Duodenum | 1 | 2016 | 112 | 0.120 |
Why?
|
| Keratinocytes | 1 | 2016 | 74 | 0.120 |
Why?
|
| Glutathione Transferase | 1 | 2016 | 145 | 0.120 |
Why?
|
| Comorbidity | 1 | 2021 | 1600 | 0.120 |
Why?
|
| Celiac Disease | 1 | 2016 | 75 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2018 | 469 | 0.120 |
Why?
|
| Phenotype | 3 | 2026 | 4528 | 0.120 |
Why?
|
| Hepatitis B, Chronic | 1 | 2016 | 87 | 0.110 |
Why?
|
| Evidence-Based Medicine | 3 | 2025 | 645 | 0.110 |
Why?
|
| Geography | 3 | 2020 | 119 | 0.110 |
Why?
|
| Schistosoma japonicum | 2 | 2012 | 8 | 0.110 |
Why?
|
| Catheter Ablation | 1 | 2018 | 317 | 0.110 |
Why?
|
| Hypertension | 2 | 2021 | 1360 | 0.110 |
Why?
|
| Apgar Score | 1 | 2014 | 50 | 0.110 |
Why?
|
| Alcoholic Beverages | 1 | 2014 | 17 | 0.110 |
Why?
|
| Hernia, Hiatal | 1 | 2014 | 58 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12997 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 342 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 682 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 423 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2017 | 328 | 0.100 |
Why?
|
| Policy Making | 1 | 2013 | 59 | 0.100 |
Why?
|
| Cohort Effect | 1 | 2012 | 5 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 570 | 0.090 |
Why?
|
| Sweden | 1 | 2012 | 58 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 303 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2015 | 240 | 0.090 |
Why?
|
| Body Weight | 1 | 2016 | 990 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2016 | 975 | 0.090 |
Why?
|
| Schistosomiasis | 1 | 2012 | 52 | 0.090 |
Why?
|
| New South Wales | 1 | 2011 | 12 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 236 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 891 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2017 | 553 | 0.090 |
Why?
|
| Schistosomiasis japonica | 1 | 2011 | 3 | 0.090 |
Why?
|
| Beer | 1 | 2011 | 4 | 0.090 |
Why?
|
| Age of Onset | 1 | 2013 | 631 | 0.090 |
Why?
|
| Wine | 1 | 2011 | 15 | 0.090 |
Why?
|
| Cattle Diseases | 1 | 2011 | 20 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2016 | 813 | 0.080 |
Why?
|
| Patient Selection | 1 | 2014 | 726 | 0.080 |
Why?
|
| Computer Terminals | 1 | 2010 | 2 | 0.080 |
Why?
|
| Pregnancy | 2 | 2014 | 7575 | 0.080 |
Why?
|
| Mutation | 1 | 2024 | 6194 | 0.080 |
Why?
|
| Sex Characteristics | 2 | 2023 | 338 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2017 | 1051 | 0.080 |
Why?
|
| Metabolic Diseases | 1 | 2010 | 137 | 0.070 |
Why?
|
| Adolescent Behavior | 1 | 2010 | 170 | 0.070 |
Why?
|
| Decision Making | 1 | 2013 | 687 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1253 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2025 | 2122 | 0.060 |
Why?
|
| alpha-Fetoproteins | 1 | 2025 | 139 | 0.050 |
Why?
|
| Child | 5 | 2021 | 26316 | 0.050 |
Why?
|
| Geography, Medical | 1 | 2023 | 17 | 0.050 |
Why?
|
| Fast Foods | 1 | 2023 | 23 | 0.050 |
Why?
|
| Muscular Diseases | 1 | 2024 | 124 | 0.050 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2023 | 40 | 0.050 |
Why?
|
| Phospholipases | 1 | 2022 | 9 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 557 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 418 | 0.050 |
Why?
|
| End Stage Liver Disease | 1 | 2024 | 191 | 0.050 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2022 | 40 | 0.050 |
Why?
|
| Sentinel Surveillance | 2 | 2012 | 26 | 0.040 |
Why?
|
| Praziquantel | 2 | 2012 | 13 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 313 | 0.040 |
Why?
|
| Anthelmintics | 2 | 2012 | 55 | 0.040 |
Why?
|
| Fatty Liver | 1 | 2023 | 220 | 0.040 |
Why?
|
| Sunburn | 1 | 2021 | 4 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2025 | 564 | 0.040 |
Why?
|
| Specialties, Nursing | 1 | 2001 | 4 | 0.040 |
Why?
|
| Pigmentation | 1 | 2021 | 35 | 0.040 |
Why?
|
| Cholagogues and Choleretics | 1 | 2020 | 24 | 0.040 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 38 | 0.040 |
Why?
|
| Cattle | 2 | 2012 | 521 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 502 | 0.040 |
Why?
|
| Observer Variation | 1 | 2001 | 319 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 199 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2019 | 88 | 0.040 |
Why?
|
| Length of Stay | 1 | 2025 | 1400 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2020 | 77 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2020 | 234 | 0.040 |
Why?
|
| Health Behavior | 1 | 2022 | 390 | 0.040 |
Why?
|
| Neurology | 1 | 2001 | 120 | 0.040 |
Why?
|
| Causality | 1 | 2018 | 92 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 97 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 192 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 1004 | 0.030 |
Why?
|
| Morbidity | 1 | 2019 | 261 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 287 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 322 | 0.030 |
Why?
|
| Weight Loss | 1 | 2021 | 529 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 2082 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 144 | 0.030 |
Why?
|
| Aftercare | 1 | 2018 | 154 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 1518 | 0.030 |
Why?
|
| Learning Curve | 1 | 2017 | 58 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 1078 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2018 | 314 | 0.030 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2016 | 67 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 548 | 0.030 |
Why?
|
| Queensland | 1 | 2016 | 4 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2016 | 109 | 0.030 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 140 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 143 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 684 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 157 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 216 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2016 | 229 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 605 | 0.030 |
Why?
|
| Colon | 1 | 2017 | 361 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2016 | 449 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 324 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2018 | 15057 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 1994 | 114 | 0.030 |
Why?
|
| Stroke | 1 | 2001 | 1049 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 825 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1610 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2012 | 83 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 807 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 1711 | 0.020 |
Why?
|
| China | 1 | 2012 | 287 | 0.020 |
Why?
|
| Taiwan | 1 | 2011 | 63 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2010 | 95 | 0.020 |
Why?
|
| Television | 1 | 2010 | 70 | 0.020 |
Why?
|
| Puberty | 1 | 2010 | 104 | 0.020 |
Why?
|
| Animals | 3 | 2018 | 34402 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8597 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 4682 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 13324 | 0.010 |
Why?
|
| Community Health Services | 1 | 2001 | 92 | 0.010 |
Why?
|
| Acute Disease | 1 | 1994 | 1153 | 0.010 |
Why?
|